Table 1 Demographic characteristics, anthropometrics and use of ongoing medications of study population according to group of treatment at baseline

Age (yr)

44.17 ± 4.98

43.59 ± 5.51

44.88 ± 6.91

45.68 ± 5.07

0.58^¥

Male sex, No (%)

15(65.2)

17(63)

19(76)

17(68)

0.76*

Known duration of diabetes (yr)

4.05 ± 4.49

3.84 ± 3.65

4.37 ± 3.25

5.97 ± 5.27

0.22^¥

Number of current smokers (%)

4(17.4)

7(25.9)

3(12)

4(16)

0.6*

Height (cm)

170.91 ± 9.83

170.13 ± 9.74

172.48 ± 8.04

170.32 ± 9.76

0.8^¥

BMI (kg/m²)

30.6 ± 3.1

31.26 ± 4.76

30.84 ± 3.28

29.59 ± 3.4

0.45^¥

Fat mass (kg)

27.23 ± 7.16

28.9 ± 10.31

26.47 ± 6.94

24.74 ± 8.27

0.35^¥

FFM (kg)

62.1 ± 11.29

61.48 ± 12.33

64.54 ± 10.95

60.58 ± 9.59

0.67^¥

Waist circumferences (cm)

107.48 ± 9.12

108.91 ± 10.9

110.26 ± 9.5

104.6 ± 6.87

0.17^¥

REE (kcal)

1833.37 ± 395.42

1859.59 ± 381.41

1865 ± 339.25

1750.09 ± 314.37

0.68^¥

Physical activity (METs h/day)

30.52 ± 5.19

30.54 ± 4.08

32.18 ± 4.39

31.75 ± 3.94

0.43^¥

 Metformin

20(87)

23(85)

23(92)

21(84)

0.84*

 DPP4 Inhibitors

6(26.1)

6(22.2)

4(16)

11(44)

0.14*

 Sulfonamide

5(21.7)

9(33.3)

10(40)

9(36)

0.57*

 Beta blocker+ABRS

6(26.1)

6(22.2)

3(12)

4(16)

0.59*

 Statin

6(26)

10(37)

10(40)

11(44)

0.61*

 Other lipid lowering gents

0

3(11.1)

2(8)

1(4)

0.38*

 Aspirin

3(13)

2(7.4)

2(8)

4(16)

0.72*